Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune responses after nonavalent HPV vaccination in healthy adolescents and adults
TCTR20250115001Completed
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Jan 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Faculty of Medicine, Chulalongkorn University. Primary endpoint: Immune response after nonavalent HPV vaccination. Started Jan 2025; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on TCTR20250115001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250115001.